Delivery Order SPE2DB20D2104-SPE2DB25FNABB
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp valued at $2,386.99 for the supply of Linzess 145 mcg capsules (30-unit quantity) with an ultimate completion date of August 5, 2025. This contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open procurement. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a $11,335.78 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Linzess 290 microgram capsules in quantities of 30 units. This firm fixed-price contract represents a competitively awarded, non-set-aside procurement with a completion date of August 19, 2025. The product will be performed and delivered from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Linzess 145 mcg capsules (30-count units) with a ceiling value of $4,586.15. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procurement procedures. The order is due for completion by September 9, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,656.64 to AmerisourceBergen Drug Corp for the supply of Linzess 290 microgram capsules (30-count units). This competitive award, issued on September 10, 2025, with an ultimate completion date of September 11, 2025, represents a firm fixed-price transaction with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performs this delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Linzess 145 microgram capsules (30-count units) valued at $9,140.32. This is a firm fixed-price, competitive delivery order with no set-aside designation and an ultimate completion date of September 15, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This...
- The Defense Logistics Agency (DLA) awarded a $3,061.96 delivery order to AmerisourceBergen Drug Corp for LINZESS 145 micrograms capsules (30-count units) on September 9, 2025, with completion targeted for September 10, 2025. This firm fixed price contract represents a non-competitive delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The award supports the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Linzess 145 micrograms capsules (30-unit package) with a contract value of $14,880.58. This firm fixed price delivery order, which is expected to be completed by August 21, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026). The award was...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Linzess 145 microgram capsules (30-count unit of use packaging) with a ceiling value of $1,676.80. This firm fixed-price delivery order, which is not set-aside for any designated small business category, is scheduled for completion by August 11, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract...
- The Defense Logistics Agency awarded a delivery order valued at $2,321.41 to AmerisourceBergen Drug Corp for the supply of Linzess 290 micrograms capsules (30-count units). This competitively awarded, firm fixed-price delivery order was executed on August 20, 2025, with an ultimate completion date of August 21, 2025. The contract represents a small-value pharmaceutical supply transaction fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order valued at $1,909.80 to AmerisourceBergen Drug Corp for Linzess 72 microgram capsules (30-count units) on September 3, 2025, with an ultimate completion date of September 4, 2025. This competitive award, which carries no set-aside designation, represents a firm fixed-price delivery order for pharmaceutical supply to support federal medical procurement needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FNABBDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Linzess 145 mcg capsules (quantity: 30 units) with a ceiling value of $1,982.96. This is a firm fixed price delivery order with an award date of September 10, 2025, and an ultimate completion date of September 11, 2025. The contract carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order falls under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999.99 billion and extends through December 2026. This prime contract vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally, including specialty medications, brand-name and generic drugs, and vaccines. As a major pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen maintains an established track record of fulfilling DLA requirements through open competition across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.0k | 9/10/25 |